2011;69(9):37983 Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE
For pancreatic cancer, large 2025 to 2026 reviews including an Annals meta-analysis found little or no increase in risk
Results The study population consisted of RA patients (N = 78, 73% females) aged 57 12 years with different degrees of periodontal inflammation
Relative contraindications requiring careful consideration and enhanced medical supervision include history of pancreatitis, severe gastrointestinal disease including gastroparesis, diabetic retinopathy (requires ophthalmologic monitoring during therapy), severe kidney disease, history of suicidal ideation or severe depression, gallbladder disease or history of cholecystitis, and age under 18 years
No Randomized Controlled Trials: As of February 2026, no published, peer-reviewed, randomized controlled trial of BPC-157 in humans exists for any indication
That became something that actually elevated it, right